Drugs

Psychoactives, nootropics, harm reduction, culture, and work.

Jun 26, 2026psilocybin / mushrooms

How Psilocybin Works

Psilocybin, psilocin, 5-HT2A receptors, default-mode network disruption, therapeutic promise, psychological risk, and why insight still needs aftercare.

5 min
Jun 26, 2026cocaine / how it works

How Cocaine Works

Dopamine, norepinephrine, serotonin, sodium channels, status theater, cardiac risk, dependence, and why borrowed confidence always sends an invoice.

5 min
Jun 26, 2026cocaine / harm reduction

Cocaine Is a UI for Status

Coke is less interesting as rebellion than as interface: speed, confidence, money, risk, and the brutal crash after borrowed charisma.

3 min
Jun 26, 2026ghb / harm reduction

GHB, Consent, and the Thin Margin

GHB sits at the brutal intersection of pleasure, risk, nightlife, consent, stigma, and the fantasy that adults can freestyle chemistry safely.

3 min
Jun 26, 2026psilocybin / lsd

Mushrooms, Acid, and the Aftercare Problem

Psychedelic culture talks endlessly about breakthrough. The harder, less merch-friendly question is what you do with yourself on Tuesday.

3 min
Jun 26, 2026salvia / psychedelics

Salvia Refuses Your Productivity Stack

Salvia is the anti-optimization drug: weird, humbling, short, and culturally useless to anyone trying to monetize transcendence.

3 min
Jun 26, 2026cannabis / privacy

Weed, Privacy, and the Group Chat

Cannabis got normalized faster than our privacy habits did. The plant may be legal-ish; the data trail is still a narc with a clipboard.

3 min
Jun 13, 2026nootropics / work

Nootropics for People Who Hate Productivity Cults

A skeptical field note on focus, ritual, caffeine, placebo, and the exhausting fantasy that every neuron should be monetized.

2 min
May 17, 2026wearables / recovery

The Morning After the Quantified Self

Wearables promised self-knowledge. Sometimes they delivered a tiny wrist tribunal with charts.

2 min